SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Sun Pharmaceutical Industries informs about press release

02 Aug 2016 Evaluate

Sun Pharmaceutical Industries has informed about a Press Release dated August 02, 2016 titled ‘Sun Pharma announces US FDA approval for generic Glumetza’.

The above information is a part of company’s filings submitted to BSE.

Sun Pharma Inds. Share Price

1874.10 26.80 (1.45%)
11-May-2026 14:36 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1874.10
Dr. Reddys Lab 1289.65
Cipla 1309.00
Zydus Lifesciences 954.70
Lupin 2281.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×